Altimmune
Developing pemvidutide across MASH, AUD, and alcohol-associated liver disease.
Something off on this page? Send us feedback.
Profile
Built around pemvidutide, a glucagon/GLP-1 dual receptor agonist, with MASH as the lead program and AUD and ALD as active mid-stage indications. Operates as a single pre-revenue segment from Gaithersburg, Maryland, relying on clinical execution, regulatory alignment, and external capital before any product sales.
Centered on pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist, with MASH as the lead indication and AUD and ALD as additional clinical programs. Legacy vaccine and HepTcell programs are not part of the current pipeline.
Operates from Gaithersburg, Maryland as a small, research-heavy team managed as a single segment. Execution now revolves around moving the MASH program into registrational development while maintaining the AUD and ALD studies.
Has not generated product sales, so the business depends on clinical readouts, FDA interactions, trial enrollment, and access to external financing. Competition spans liver-disease and incretin mechanisms from larger pharmaceutical companies and specialist biotech developers.
Company facts
Key statistics
Year to date −11.0% · Average volume (30d) 4.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| Jun 22, 2026 | Leerink Partners | Target | $10 | |
| Apr 24, 2026 | Goldman Sachs | Target | $20 | $2.50 |
| Jan 27, 2026 | Barclays | Target | $20 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.14 | −$0.12 | +11.4% | $2.0K | $46.0K | +2,200.0% | −2.33% |
| May 13, 2026Q1 FY26 | −$0.25 | −$0.18 | +28.0% | $1.4K | — | — | −3.31% |
| Mar 5, 2026Q4 FY25 | −$0.25 | −$0.27 | −8.0% | $556 | $26.0K | +4,576.3% | +0.85% |
| Nov 6, 2025Q3 FY25 | −$0.29 | −$0.21 | +27.6% | $560 | $5.0K | +792.9% | +4.31% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $5.0K | $5.0K | $26.0K | $0 | $0 | |
| Gross profit | $5.0K | $5.0K | −$15.0M | $26.0K | −$23.0K | −$23.0K | |
| Operating income | −$21.8M | −$22.9M | −$20.9M | −$28.9M | −$24.2M | −$26.2M | |
| Net income | −$19.6M | −$22.1M | −$19.0M | −$27.4M | −$22.6M | −$22.8M | |
| Diluted EPS | −$0.26 | −$0.27 | −$0.21 | −$0.27 | −$0.18 | −$0.12 | |
| Gross margin | 100.0% | 100.0% | -299,100.0% | 100.0% | — | — | |
| Operating margin | -436,300.0% | -458,440.0% | -417,180.0% | -111,126.9% | — | — |
Fiscal years (4-quarter sums)FY21 $4.4M · FY22 −$68.0K · FY23 $426.0K · FY24 $20.0K · FY25 $41.0K
Balance sheet, Jun 30, 2026Cash & short-term investments $326.3M · Total debt $35.7M · Total assets $527.2M · Shareholders' equity $474.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 194.47M · Float 183.67M · 94.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.39M | 10.48% | 13F | Aug 7, 2026 |
| Deep Track Capital, LP | 19.25M | 9.90% | 13F | Aug 14, 2026 |
| State Street Corp | 12.10M | 6.22% | 13F | Aug 7, 2026 |
| TCG Crossover Management, LLC | 10.00M | 5.14% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 8.18M | 4.21% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Jerome Benedict Durso | director, officer: President and CEO | +15,000 | $2.95 |
| Apr 6, 2026 | John Gill | director | +9,200 | $3.41 |
| Apr 1, 2026 | Jerome Benedict Durso | director, officer: President and CEO | +15,000 | $3.14 |
| Apr 1, 2026 | Gregory L. Weaver | officer: Chief Financial Officer | +10,000 | $3.15 |
| Mar 6, 2026 | Jerome Benedict Durso | director, officer: President and CEO | +20,000 | $3.54 |
Peers
- Madrigal Pharmaceuticals
Approved MASH THR-beta benchmark with Rezdiffra
- Novo Nordisk (ADR)
Approved GLP-1 MASH entrant with broad metabolic scale
- Eli Lilly
Incretin challenger in MASH and obesity-linked liver disease
- Viking Therapeutics
Clinical THR-beta challenger with VK2809 MASH data
- GSK (ADR)
Hepatology pipeline overlap in MASH and ALD
- Alkermes
Approved AUD treatment benchmark through Vivitrol
- Inventiva (ADR)
Phase 3 oral pan-PPAR challenger in MASH
- Aligos Therapeutics
Early THR-beta MASH challenger with ALG-055009
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Altimmune | $3.12 | −0.12% | $604.8M | — | — | 19,510.1 | +820.0% |
| Madrigal Pharmaceuticals | $533.76 | −0.02% | $12.33B | — | — | 9.6 | +71.2% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Viking Therapeutics | $32.24 | +0.31% | $3.75B | — | — | — | — |
| GSK (ADR) | $50.57 | −0.51% | $101.82B | 15.8 | 9.2 | 2.2 | +2.7% |
| Alkermes | $47.25 | −0.34% | $7.95B | 123.8 | — | 4.8 | +27.0% |
| Inventiva (ADR) | $4.71 | 0.00% | $244.6M | — | — | 210.8 | — |
| Aligos Therapeutics | $7.02 | +2.48% | $42.8M | — | — | 1.4 | +2,778.6% |
| Median | 27.6 | 18.4 | 4.8 | +37.3% |